Trials / Completed
CompletedNCT00308724
Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Baylor College of Medicine · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether cognitive behavior therapy (CBT) is effective in the treatment of generalized anxiety disorder (GAD) in adults age 60 and older in a primary care setting.
Detailed description
Generalized Anxiety Disorder (GAD) is one of the most common anxiety disorders among older adults. Anxiety in older adults is associated with decreased physical activity, poorer self-perceptions of health, decreased life satisfaction, and increased loneliness. Because many older adults with anxiety seek assistance in a medical setting, treatment has been primarily pharmacological. There is, however, limited evidence of the effectiveness of psychotropic medications. Given the potential difficulties in prescribing psychotropic medications in later life (e.g., increased adverse effects, potential drug interactions), psychosocial treatments may be important alternative or adjuncts. The treatment phase of this study lasts 10 weeks, during which patients will be randomly assigned to either cognitive behavior therapy (CBT) or usual care. Follow-up will last 12 months after treatment completion, during which time patients will complete telephone assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Cognitive Behavior Therapy | 8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period |
| BEHAVIORAL | Telephone check-in | Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2008-01-01
- Completion
- 2015-04-01
- First posted
- 2006-03-30
- Last updated
- 2024-03-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00308724. Inclusion in this directory is not an endorsement.